Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 2/20 | 0.52 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | JAK1 | P23458 | 7/20 | 0.41 |
| ▸ | JAK2 | O60674 | 6/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.40 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.40 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.39 |
| ▸ | MMP13 | P45452 | 1/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20037390 | 0.85 | GPR119 (0.52) | GPR119NR1H2JAK1JAK2HDAC1 | |
| SCHEMBL3356420 | 0.85 | KDM1A (0.46) | JAK1JAK2HDAC1MEN1KMT2A | |
| SCHEMBL16987051 | 0.83 | GPR119 (0.51) | GPR119NR1H2JAK1JAK2HDAC1 | |
| SCHEMBL16987015 | 0.82 | PKM (0.51) | GPR119NR1H2JAK1JAK2HDAC1 | |
| SCHEMBL7840200 | 0.81 | LMNA (0.45) | GPR119JAK1JAK2ALDH1A1 | |
| SCHEMBL23864080 | 0.81 | GPR119 (0.54) | GPR119NR1H2JAK1JAK2ALDH1A1 | |
| SCHEMBL20037400 | 0.80 | GPR119 (0.53) | GPR119NR1H2JAK1JAK2 | |
| SCHEMBL21388108 | 0.80 | GPR119 (0.48) | GPR119NR1H2JAK1JAK2HDAC1 | |
| SCHEMBL1221599 | 0.80 | KDM1A (0.48) | HDAC1HDAC8HDAC6ALDH1A1MEN1 | |
| SCHEMBL16987073 | 0.79 | JAK2 (0.44) | JAK1JAK2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2022-02-15 | — | — | US | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| EP-3626713-B1 | CYCLOPROPYLAMINES FOR USE AS LSD1 INHIBITORS | INCYTE CORP (US) | 2021-09-29 | — | — | EP | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2021-02-04 | — | — | US | disclosed |
| CN-111454188-A | Cyclopropylamines as L SD1inhibitors | 因赛特公司 | 2020-07-28 | — | — | CN | disclosed |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-07-21 | — | — | US | disclosed |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2020-07-21 | — | — | US | disclosed |
| EP-3626713-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2020-03-25 | — | — | EP | disclosed |
| US-20170112816-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION | 2017-04-27 | — | — | US | disclosed |
| EP-3105219-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-3105218-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Incyte Corporation (US) | 2016-12-21 | — | — | EP | disclosed |
| US-9493442-B2 | Cyclopropylamines as LSD1 inhibitors | INCYTE CORPORATION (US) | 2016-11-15 | — | — | US | disclosed |
| WO-2015123408-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123465-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123408-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| WO-2015123465-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-20 | — | — | WO | disclosed |
| US-20150225379-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | INCYTE CORPORATION (US) | 2015-08-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225401-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | GPR119 1776/4885NR1H2 409/4885JAK1 4383/4885 |
| US-10717737-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | GPR119 1776/4885NR1H2 409/4885JAK1 4383/4885 |
| US-20150225379-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | GPR119 1776/4885NR1H2 409/4885JAK1 4383/4885 |
| US-11247992-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM2A | GPR119 1776/4885NR1H2 409/4885JAK1 4383/4885 |
| US-20170112816-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | GPR119 1776/4885NR1H2 409/4885JAK1 4383/4885 |
| US-20210032244-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM2A | GPR119 1776/4885NR1H2 409/4885JAK1 4383/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.